Seer Reports Third Quarter 2023 Financial Results
Expanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence
REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2023.
- Achieved revenue of $4.2 million for the third quarter of 2023, an increase of 5% over the prior year period
- Expanded geographically with two new partners - Danyel Biotech in Israel and GeneTiCA in Eastern Europe
- Added Panome Bio to Centers of Excellence program to deliver innovative multi-omics services
- Demonstrated value of Proteograph Product Suite through increased customer publications available on bioRxiv
- Received ISO 27001 certification for increased information security and cybersecurity standards; ISO 13485 certification for quality management and to enable the utilization of products in FDA submissions
- Ended the quarter with $380.8 million of cash, cash equivalents and investments
“Our team made progress during the third quarter to drive adoption of the Proteograph Product Suite despite the ongoing macroeconomic headwinds impacting our customers,” said Omid Farokhzad, CEO and President. “It is encouraging to see more customer manuscripts move through the peer-review process. I am confident that as more third-party data and publications demonstrate the power of our differentiated technology, we will see increasing adoption of our technology.”
Third Quarter 2023 Financial Results
Revenue was $4.2 million for the three months ended September 30, 2023, a 5% increase from $4.0 million for the three months ended September 30, 2022. The increase was primarily due to increased instrument sales, services, and grant and other revenue, offset by lower consumables sales. Product-related revenue for the third quarter of 2023 was $3.3 million, including $1.4 million of related party revenue, and consisted of sales of SP100 instruments and consumable kits. Service revenue was $536 thousand and grant and other revenue was $348 thousand.
Gross profit, inclusive of grant and other revenue, was $2.2 million and gross margin was 52% for the third quarter of 2023.
Operating expenses were $28.0 million for the third quarter of 2023, including $8.3 million of stock-based compensation, an increase of 4%, as compared to $27.0 million, including $9.1 million of stock-based compensation, for the corresponding prior year period. The increase in expenses was primarily driven by an increase in product development efforts related to the Proteograph Product Suite, including employee compensation and other related expenses, offset by a decrease in professional services.
Net loss was $21.1 million for the third quarter of 2023, as compared to $24.0 million for the corresponding prior year period.
Cash, cash equivalents and investments were $380.8 million as of September 30, 2023.
Given the Company’s performance year to date as well as the ongoing challenges in the current macroeconomic environment, Seer anticipates coming in at the lower half of its revenue guidance range of $16 million to $18 million.
Seer will host a conference call to discuss the third quarter 2023 financial results on Tuesday, November 7, 2023 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the Company’s current views with respect to certain current and future events and financial performance. Words such as “expects,” “anticipates,” “projects,” “intends,” “plans,” “believes,” “estimates,” variations of such words, and similar expressions are also intended to identify such forward-looking statements. Such forward-looking statements are based on the Company’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding the Company’s outlook for fiscal year 2023. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Quarterly Report on Form 10-Q, to be filed with the SEC, and other documents the Company subsequently files with the SEC from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
|Three Months Ended September 30,||Nine Months Ended September 30,|
|Grant and other||348||—||1,221||64|
|Cost of revenue:|
|Grant and other||334||—||462||—|
|Total cost of revenue||2,006||2,010||5,718||6,090|
|Research and development||13,232||11,564||41,854||33,167|
|Selling, general and administrative||14,769||15,447||45,882||43,917|
|Total operating expenses||28,001||27,011||87,736||77,084|
|Loss from operations||(25,845||)||(25,066||)||(81,231||)||(72,286||)|
|Other income (expense):|
|Total other income||4,757||1,086||12,753||1,845|
|Other comprehensive loss:|
|Unrealized gain (loss) on available-for-sale securities||236||420||(45||)||(2,157||)|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.33||)||$||(0.38||)||$||(1.07||)||$||(1.13||)|
|Weighted-average common shares outstanding, basic and diluted||63,929,743||62,538,983||63,747,155||62,308,314|
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
|September 30,||December 31,|
|Cash and cash equivalents||$||36,396||$||53,208|
|Accounts receivable, net||5,492||4,315|
|Related party receivables||1,502||1,804|
|Prepaid expenses and other current assets||2,903||2,098|
|Total current assets||346,122||434,982|
|Operating lease right-of-use assets||25,774||27,003|
|Property and equipment, net||21,730||19,408|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Operating lease liabilities, current||2,310||1,842|
|Other current liabilities||123||207|
|Total current liabilities||12,518||12,584|
|Operating lease liabilities, net of current portion||26,499||28,032|
|Other noncurrent liabilities||157||320|
|Commitments and contingencies|
|Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of September 30, 2023 |
and December 31, 2022; zero shares issued and outstanding as of September 30, 2023 and
December 31, 2022
|Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of September 30, |
2023 and December 31, 2022; 59,932,008 and 59,366,077 shares issued and outstanding as of
September 30, 2023 and December 31, 2022, respectively
|Class B common stock, $0.00001 par value; 6,000,000 shares authorized as of September 30, |
2023 and December 31, 2022; 4,044,969 shares issued and outstanding as of September 30,
2023 and December 31, 2022
|Additional paid-in capital||694,948||667,739|
|Accumulated other comprehensive loss||(1,296||)||(1,251||)|
|Total stockholders’ equity||405,679||446,993|
|Total liabilities and stockholders’ equity||$||444,853||$||487,929|